Trials / Completed
CompletedNCT00716859
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 139 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 36 Weeks – 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Timolol | Timolol 0.5% dosed twice-daily |
| DRUG | latanoprost | Latanoprost 0.005% ophthalmic solution dosed once-daily |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2008-07-16
- Last updated
- 2021-02-03
- Results posted
- 2010-12-02
Locations
48 sites across 20 countries: United States, Belgium, Colombia, Czechia, France, Germany, India, Italy, Philippines, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, South Africa, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00716859. Inclusion in this directory is not an endorsement.